Share this article
Share this article
SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.
The newly announced data are from a phase 2 trial evaluating pelareorep in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in pancreatic adenocarcinoma patients who progressed after first-line treatment. Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, which is mediated through the complementary immunotherapeutic effects of the two agents.
Share this article
STOCKHOLM, May 20, 2021 /PRNewswire/
Medivir AB (Nasdaq Stockholm: MVIR) today announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma (SCC). The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors. This clinical study was conducted at the Stanford University School of Medicine in California, USA under the leadership of the principal investigator, Dr Kavita Sarin. Medivir is providing remetinostat drug supply for this study, and has full access to, and the rights to use, all clinical data after the study is complete.
Share this article
Share this article
TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December 2019 generating a US$3 million milestone payment at that time.
Pfizer nominated three distinct clinical candidates from the collaboration with Sosei Heptares during 2019, all of which are now progressing in Phase I clinical trials. These candidates have also now been disclosed by Pfizer as:
Share this article
Share this article
HANGZHOU and SHAOXING, China, May 4, 2021 /PRNewswire/ Ascletis Pharma Inc. (HKEX:1672) today announces the positive Phase IIa clinical results of ASC22 (Envafolimab), which is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure.
ASC22 Phase IIa clinical trial is a single dose escalation study of three subcutaneously administered doses (0.3, 1.0 and 2.5 mg/kg, three patients per dose) with 12-week follow-up to explore the safety and preliminary efficacy of ASC22 in CHB patients (ClinicalTrials.gov Identifier: NCT04465890). The primary efficacy endpoint is HBsAg reduction during 12-week follow-up after the single dose administration. Median baseline HBsAg of nine CHB patients enrolled was 3.0 log
Share this article
WATERTOWN, Mass., May 5, 2021 /PRNewswire/ A new study
1 published by JAMA Network proves that individuals, in this case, young, healthy, male basketball players, who tested positive for COVID-19 but were asymptomatic, did not spread the virus despite being in a closed, isolation bubble over a period of months.
Over approximately four months, nearly 4,000 basketball players, staff, and vendors interacted in indoor, unmasked, close contact activities that involved direct exposure between persistent positive cases and noninfected individuals. All the people in the closed environment participated in a regular, supervised testing program. The study concluded that recovered individuals who continued to test positive for SARS-CoV-2 following discontinuation of isolation were not infectious to others.